Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soil-derived microbiota induces T regulatory cells and protect against mouse colitis, metabolic disease, and sepsis.

Gut microbes·2026
Same author

A Novel CsYABBY3-CsAS1 Feedback Loop Coordinates Trichome Differentiation and Cannabinoid Biosynthesis in Cannabis sativa L.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Acute-on-chronic liver failure due to hepatitis B.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Characterization of the complete chloroplast genome of <i>Aesculus pavia</i>.

Mitochondrial DNA. Part B, Resources·2026
Same author

The complete chloroplast genome and phylogenetic analysis of <i>Fraxinus paxiana</i> Lingelsh. 1907 (Oleaceae).

Mitochondrial DNA. Part B, Resources·2026
Same author

Stirring chemical reaction landscapes through strong light-matter interactions.

Chemical communications (Cambridge, England)·2025

Related Experiment Video

Updated: Mar 10, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K

CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice.

Brandon S B Canup1, Heliang Song1, Vu Le Ngo2

  • 1Department of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|December 13, 2016
PubMed
Summary
This summary is machine-generated.

Targeting CD98 expression with siRNA-loaded nanoparticles significantly reduced non-alcoholic fatty liver disease (NAFLD) markers in mice. This novel nanoparticle approach shows promise for treating NAFLD by reducing liver lipids and inflammation.

Keywords:
Hepatic CD98Nonalcoholic fatty liverTargeted therapeutic strategysiRNA-loaded nanoparticles

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K

Related Experiment Videos

Last Updated: Mar 10, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K

Area of Science:

  • Hepatology
  • Nanomedicine
  • Molecular Biology

Background:

  • Non-alcoholic fatty liver disease (NAFLD) involves excessive lipid accumulation in the liver.
  • Current therapeutic strategies for NAFLD are limited.
  • CD98 is implicated in cellular processes relevant to liver disease.

Purpose of the Study:

  • To investigate the therapeutic potential of reducing CD98 expression using siRNA-loaded nanoparticles (NPs) in a mouse model of NAFLD.
  • To evaluate the efficacy of NPs in attenuating NAFLD markers both in vitro and in vivo.

Main Methods:

  • NAFLD was induced in mice using a high-fat diet.
  • CD98 siRNA-loaded NPs were synthesized via double emulsion/solvent evaporation.
  • Mice received intravenous tail injections of NPs.
  • In vitro studies utilized HepG2 cells.
  • NAFLD markers, including liver enzymes, lipids, fibrosis, and cytokines, were assessed.

Main Results:

  • In vitro, CD98 siRNA-loaded NPs effectively downregulated CD98 expression in HepG2 cells, reducing pro-inflammatory cytokines.
  • In vivo, NP treatment significantly decreased NAFLD markers, including serum ALT levels, hepatic lipid accumulation, fibrosis, and pro-inflammatory cytokines.
  • The nanoparticle delivery system demonstrated efficacy in reducing key indicators of liver disease.

Conclusions:

  • CD98 plays a crucial role in the pathogenesis of NAFLD.
  • siRNA-loaded nanoparticles targeting CD98 represent a promising therapeutic strategy for NAFLD.
  • This targeted nanoparticle approach offers a potential new avenue for NAFLD treatment.